Evidence map›Paper›PMID 42135919›Full record

ArticleAnnals of clinical and translational neurology2026

Peripheral Neutrophil Activation and Extracellular Trap Formation in Amyotrophic Lateral Sclerosis.

Lillia A Baird, Haley McQuown, Jihyun Park, Samuel J Teener, Ian F Webber-Davis, Andrew D Carter, Dae-Gyu Jang, Eva L Feldman, Stephen A Goutman, Benjamin J Murdock

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lillia A BairdDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-3209-8754
Haley McQuownDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Jihyun ParkDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Samuel J TeenerDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Ian F Webber-DavisDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Andrew D CarterDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0009-0006-7953-8998
Dae-Gyu JangDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0009-0009-7966-1322
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-9162-2694
Stephen A GoutmanDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0001-8780-6637
Benjamin J MurdockDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-3543-4007

Funding

RESEARCH TRAINING IN EXPERIMENTAL IMMUNOPATHOLOGYT32AI007413 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Bethany B. Moore · 1993 to 2026
$9.8M
Mapping the ALS Exposome to Gain New Insights into Disease Risk and PathogenesisR01ES030049 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BATTERMAN, STUART A, FELDMAN, EVA LUCILLE · 2020 to 2024
$3.5M
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohortR01NS127188 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BATTERMAN, STUART A, FELDMAN, EVA LUCILLE · 2021 to 2024
$3.4M
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signaturesR01NS120926 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GOUTMAN, STEPHEN, MURDOCK, BENJAMIN JOSEPH · 2021 to 2025
$3.0M
The Role of Neutrophil Heterogeneity and Molecular Mechanisms in Driving ALSF31NS139629 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BAIRD, LILLIA · 2024 to 2025
$87k
ACL HHS R01TS000339ACL HHS U01TS000351ATSDR CDC HHS R01 TS000339ATSDR CDC HHS U01 TS000351Coleman Therapeutic Discovery FundMichael R. Johns FundNeuroNetwork for Emerging TherapiesNIAID NIH HHS T32 AI007413NIEHS NIH HHS R01 ES030049NIH HHS F31NS139629NIH HHS R01ES030049NIH HHS R01NS120926NIH HHS R01NS127188NIH HHS T32AI007413NINDS NIH HHS F31 NS139629NINDS NIH HHS R01 NS120926NINDS NIH HHS R01 NS127188Peter R. Clark Fund for ALS ResearchRichard Stravitz FoundationRobert A. Epstein and Joan M. Chernoff-Epstein Emerging Scholar FundScott Pranger ALS Center, the Dr. Randall Whitcomb Fund for ALS Genetics, the Coleman Therapeutic Discovery Fund, James and Margaret Hiller, Eric and Linda NovakStanford Morris ALS Research Fund
6 · The paper itself

Abstract

objectivesPeripheral neutrophil levels in amyotrophic lateral sclerosis (ALS) inversely correlate with survival, suggesting a role for neutrophils in disease progression. Here, we characterize markers of several neutrophil activation pathways and evaluate their associations with survival to identify potential mechanisms of disease.

methodsBlood samples were obtained from participants at the University of Michigan ALS Clinic or from healthy controls. Ex vivo neutrophil extracellular trap (NET) formation was quantified via image analysis of primary neutrophils. Neutrophil function markers of general activation (calprotectin), migration (matrix-metalloproteinase 9 [MMP9]), and degranulation (neutrophil gelatinase-associated lipocalin [NGAL]) were then quantified in plasma via ELISA; NET formation (double-stranded DNA [dsDNA]) was assessed via fluorescence assay. These markers were then associated with ALS survival using Cox proportional hazard regression models, and analyses were stratified by sex.

resultsSpontaneous ex vivo NET formation (N = 20 controls, 66 ALS) was increased in ALS (1.0% vs. 9.7%; p = 0.017). In plasma (N = 233 controls, 178 ALS), calprotectin (294 vs. 372 ng/mL; p < 0.001), MMP9 (106 vs. 152 ng/mL; p < 0.001), and NGAL (61 vs. 66 ng/mL; p = 0.01) were elevated in ALS. Calprotectin, MMP9, and NGAL levels were not associated with ALS survival; however, dsDNA was associated with poorer ALS survival but only in females (HR = 1.77 [95% CI, 1.20-2.61]; p = 0.004).

interpretationNeutrophil function is altered in ALS, and NET formation is a potential mechanism by which neutrophils contribute to ALS, particularly in females.

Indexed as

ALSimmune systemmotor neuron diseaseneutrophils

Identifiers

PMID42135919
PMCPMC13394124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.